Murli Krishna Pharma Disrupts Global Ophthalmic Market; Unveils Next-Gen PUREZOL™ Platform at 17th Pharma Leaders Summit
Pharma Icon Dr. Satya Ramani Vadlamani Commands the Stage in Mumbai, Merging Visionary Women Leadership with a Revolutionary NDDS Breakthrough that Outperforms Current Market-Leading Glaucoma Therapies.
At the prestigious 17th Annual Pharma Leaders Healthcare Leadership Summit & Power Brand Awards 2026—widely regarded as the “Oscars of Indian Healthcare”Dr. Satya Ramani Vadlamani, Chairperson & Managing Director of Murli Krishna Pharma Pvt. Ltd. (MKPPL), delivered a definitive keynote address fitting this year’s progressive theme: “Reimagining Healthcare – Powering Trust, Innovation & Global Impact.”
Speaking on “A Woman of Substance: Breaking Barriers: Engineering the Future of Pharma: The Next Frontier in NDDS and Patient-Centric Formulations,” Dr. Vadlamani showcased how visionary female leadership and advanced particle engineering are fundamentally shifting the boundaries of drug delivery to improve global patient outcomes.
Breaking Barriers in NDDS: Dr. Satya Ramani Vadlamani Ignites the 17th Annual Pharma Leaders Summit. #PharmaLeaders2026 #DrSatyaVadlamani #WomenInPharma #NovelDrugDelivery #NDDS #OphthalmicInnovation #PUREZOL #GlaucomaTherapy #ParticleEngineering #MurliKrishnaPharma #MKPPL pic.twitter.com/lkA6TSAOsj
— Pharmaleaders (@pharmaleader) July 1, 2026
The Next Frontier: Introducing the PUREZOL™ Platform
As a real-world manifestation of the summit’s theme, Murli Krishna Pharma proudly introduced its groundbreaking PUREZOL™ Platform—an advanced, proprietary particle engineering technology designed to optimize ophthalmic suspensions through precise particle-size reduction and enhanced ocular delivery.
Disrupting the Glaucoma Care Paradigm
- The Nano-Scale Breakthrough: The PUREZOL™ platform has successfully reduced the particle size of Brinzolamide to below 2 microns.
- The Market Comparison: Conventional, market-leading ophthalmic suspensions typically lag behind in the 5–6 micron range.
- Clinical Superiority: By shrinking the particle size, PUREZOL™ delivers enhanced ocular surface coverage, drastically improved corneal penetration, optimized drug bioavailability, and superior overall therapeutic performance.
Beyond a Single Product: PUREZOL™ is a highly versatile, scalable ophthalmic platform tech engineered to seamlessly integrate across multiple glaucoma therapies and Fixed-Dose Combinations (FDCs), including: Brinzolamide, Dorzolamide, Timolol, Brimonidine, Pilocarpine, Latanoprost, Travoprost, Bimatoprost, and Tafluprost.
Why Global Giants Partner with MKPPL
As MKPPL redefines patient-centric formulations, they offer global pharmaceutical companies an unrivaled pipeline acceleration model built on world-class foundations:
- EU-GMP Certified Infrastructure: State-of-the-art manufacturing designed for absolute compliance.
- Complex Engineering Expertise: Decades of proven leadership in stable complex suspensions and Novel Drug Delivery Systems (NDDS).
- End-to-End Capabilities: From nimble laboratory R&D to large-scale commercial manufacturing.
- Flexible Collaboration Models: Tailored options for Licensing, CDMO, Technology Transfer, and Co-Development.
- Global Footprint: Seamless regulatory navigating across 78+ countries.
